| 产品名称： | HuNS1 |
|---|---|
| 商品货号： | TS211815 |
| Organism： | Homo sapiens, human |
| Cell Type： | lymphoblast |
| Product Format： | frozen |
| Morphology： | lymphoblast |
| Culture Properties： | suspension |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease： | myeloma |
| Gender： | male |
| Storage Conditions： | liquid nitrogen vapor phase |
| Disclosure： | This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC. |
| Derivation： | This line was derived from the GM4672 cell line (Human Genetic Mutant Cell Repository, Coriell Institute for Medical Research) following treatment with ethylmethanesulfonate (EMS). |
| Clinical Data： | male |
| Comments： | The cells are HAT sensitive and are negative for Epstein-Barr virus. According to information provided by the patent depositor (US Patent 4,720,459 dated Jan 19 1988), this cell line did not secrete an immunoglobulin. However, recent testing at ATCC has confirmed the presence of IgG. |
| Complete Growth Medium： | RPMI 1640 medium with 2 mM L-glutamine, 4.5g/L glucose, 10 mM HEPES, 1 mM sodium pyruvate, 1.5 g/L sodium bicarbonate, 0.02 mM 2-amino-6-methylmercaptopurine, 85%; fetal bovine serum, 15%
|
| Subculturing： | Cultures can be maintained by addition of fresh medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 2 x 105xa0viable cells/mL. Maintain cultures at a cell concentration between 1 x 105 and 1 x 106xa0cells/mL.
Medium Renewal: Every 2 to 3 days |
| Cryopreservation： | Complete Culture Medium, 95%; DMSO, 5%.xa0Cell culture tested DMSO is available as ATCC Catalog No. 4-X.
|
| Culture Conditions： | Temperature: 37°C |
| STR Profile： | Amelogenin: X,Y CSF1PO: 10,12 D13S317: 12 D16S539: 11 D5S818: 10,12 D7S820: 10 THO1: 9,9.3 TPOX: 8 vWA: 16,19 |
| Name of Depositor： | Medical College of Wisconsin Research Foundation, Inc. |
| Deposited As： | Homo sapiens |
| U.S. Patent Number： | |
| References： | Winkelhake JL. Myelomas for producing human/human hybridomas. US Patent 4,720,459 dated Jan 19 1988 Hay, R. J., Caputo, J. L., and Macy, M. L., Eds. (1992), ATCC Quality Control Methods for Cell Lines. 2nd edition, Published by ATCC. Caputo, J. L., Biosafety procedures in cell culture. J. Tissue Culture Methods 11:223-227, 1988. Fleming, D.O., Richardson, J. H., Tulis, J.J. and Vesley, D., (1995) Laboratory Safety: Principles and Practice. Second edition, ASM press, Washington, DC. |
产品中心 Product Center
联系我们CONTACT US
-
0574-87917803
24小时服务热线 -
testobio@163.com
销售邮箱 -
浙江省宁波市高新区晶辉路866弄33号智造港E4幢3楼
地址
联系方式
-
章丽敏
17757489010 -
朱静
18067106081 -
李晴
18067408036 -
李晶晶
13375187189 -
周雪
13372109301
| 产品名称： | HuNS1 |
|---|---|
| 商品货号： | TS211815 |
| Organism： | Homo sapiens, human |
| Cell Type： | lymphoblast |
| Product Format： | frozen |
| Morphology： | lymphoblast |
| Culture Properties： | suspension |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease： | myeloma |
| Gender： | male |
| Storage Conditions： | liquid nitrogen vapor phase |
| Disclosure： | This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC. |
| Derivation： | This line was derived from the GM4672 cell line (Human Genetic Mutant Cell Repository, Coriell Institute for Medical Research) following treatment with ethylmethanesulfonate (EMS). |
| Clinical Data： | male |
| Comments： | The cells are HAT sensitive and are negative for Epstein-Barr virus. According to information provided by the patent depositor (US Patent 4,720,459 dated Jan 19 1988), this cell line did not secrete an immunoglobulin. However, recent testing at ATCC has confirmed the presence of IgG. |
| Complete Growth Medium： | RPMI 1640 medium with 2 mM L-glutamine, 4.5g/L glucose, 10 mM HEPES, 1 mM sodium pyruvate, 1.5 g/L sodium bicarbonate, 0.02 mM 2-amino-6-methylmercaptopurine, 85%; fetal bovine serum, 15%
|
| Subculturing： | Cultures can be maintained by addition of fresh medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 2 x 105xa0viable cells/mL. Maintain cultures at a cell concentration between 1 x 105 and 1 x 106xa0cells/mL.
Medium Renewal: Every 2 to 3 days |
| Cryopreservation： | Complete Culture Medium, 95%; DMSO, 5%.xa0Cell culture tested DMSO is available as ATCC Catalog No. 4-X.
|
| Culture Conditions： | Temperature: 37°C |
| STR Profile： | Amelogenin: X,Y CSF1PO: 10,12 D13S317: 12 D16S539: 11 D5S818: 10,12 D7S820: 10 THO1: 9,9.3 TPOX: 8 vWA: 16,19 |
| Name of Depositor： | Medical College of Wisconsin Research Foundation, Inc. |
| Deposited As： | Homo sapiens |
| U.S. Patent Number： | |
| References： | Winkelhake JL. Myelomas for producing human/human hybridomas. US Patent 4,720,459 dated Jan 19 1988 Hay, R. J., Caputo, J. L., and Macy, M. L., Eds. (1992), ATCC Quality Control Methods for Cell Lines. 2nd edition, Published by ATCC. Caputo, J. L., Biosafety procedures in cell culture. J. Tissue Culture Methods 11:223-227, 1988. Fleming, D.O., Richardson, J. H., Tulis, J.J. and Vesley, D., (1995) Laboratory Safety: Principles and Practice. Second edition, ASM press, Washington, DC. |
